# EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.

> **NIH NIH N43** · SILVER LAKE RESEARCH CORPORATION · 2020 · $600,000

## Abstract

The proposal addressed the need for novel monoclonal Abs (MAbs) to characterize subsets of immune cells and cytokines in the guinea pig model. The goal is to use their novel technology to produce high-affinity MAbs against six target antigens, focusing on surface markers of immune cells, and to characterize the specificity of antibodies with guinea pig PBMCs and tissue section. These new reagents will be available to significantly enhance research capabilities for tuberculosis and other diseases such as influenza, Ebola and Zika viral infections.

## Key facts

- **NIH application ID:** 10291475
- **Project number:** 75N93020C00024-0-9999-1
- **Recipient organization:** SILVER LAKE RESEARCH CORPORATION
- **Principal Investigator:** MARK GEISBERG
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $600,000
- **Award type:** —
- **Project period:** 2020-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10291475

## Citation

> US National Institutes of Health, RePORTER application 10291475, EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS. (75N93020C00024-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10291475. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*